[Clinical evaluation of cinnoxicam 30 mg in patients with osteoarthrosis. A double-blind controlled study].
We tested the therapeutic response of osteoarthrosis subjects to piroxicam cinnamate 30 mg tablets (Sinartrol). The double-blind study was conducted in 2 homogeneous groups of 30 patients each treated with piroxicam cinnamate one 30 mg tablet twice daily for 2 days followed by 1 tablet daily for 13 more days and with piroxicam cinnamate 20 mg tablets (according to the same posologic scheme) respectively. The results obtained demonstrate the efficacy of this new piroxicam cinnamate formulation which led to a significant clinical improvement, already evident after 2 days of treatment and even more evident at the end of therapy. Patients' compliance to treatment was good and side effects were scarce and spontaneously subsiding.
Bestetti
F
F
Clinica Ortopedica, Ospedale San Gerardo, Monza (Milano).
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D003627:Data Interpretation, Statistical; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy*; D010894:Piroxicam / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; C057291:piroxicam cinnamate
Valutazione clinica del cinnoxicam 30 mg in pazienti affetti da osteoartrosi. Studio controllato in doppio cieco.